ACRX - AcelRx Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD

AcelRx Pharmaceuticals, Inc.

351 Galveston Drive
Redwood City, CA 94063
United States

IndustryMedical Appliances & Equipment
Full Time Employees41

Key Executives

NameTitlePayExercisedYear Born
Dr. Pamela Pierce Palmer M.D., Ph.D.Co-Founder, Chief Medical Officer and Director645.61kN/A1963
Ms. Jane Wright-MitchellChief Legal Officer457.32kN/A1969
Mr. Lawrence G. HamelChief Devel. Officer457.99kN/A1952
Mr. Anil N. DasuChief Engineering Officer457.99kN/A1963
Mr. Vincent J. AngottiCEO & DirectorN/AN/A1968
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet, which is in Phase III clinical trial for the treatment of moderate-to-severe acute pain. The company's late-stage investigational product candidate is Zalviso, a pre-programmed and patient-controlled analgesia device that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain. Zalviso is approved in the European Union, Switzerland, Liechtenstein, Iceland, Norway and Australia, or the Territory; and is under development stage in the United States. The company was formerly known as SuRx Pharmaceuticals, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Redwood City, California.

Corporate Governance

AcelRx Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.